The role of pharmacogenomics in adverse drug reactions

References

• Shoshi A, Hoppe T, Kormeier B, et al. GraphSAW: a web-based system for graphical analysis of drug interactions and side effects using pharmaceutical and molecular data. BMC Med Inform Decis Mak. 2015;15:15.
   PubMed Web of Science ®Google Scholar
• Rankin A, Cadogan CA, Patterson SM, et al. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev. 2018;9:CD008165.
   PubMedGoogle Scholar
• Sönnichsen A, Trampisch US, Rieckert A, et al. Polypharmacy in chronic diseases-reduction of inappropriate medication and adverse drug events in older populations by electronic decision support (PRIMA-eDS): study protocol for a randomized controlled trial. Trials. 2016;17:57.
   PubMed Web of Science ®Google Scholar
• Cacabelos R. Molecular pathology and pharmacogenomics in Alzheimer’s disease: polygenic-related effects of multifactorial treatments on cognition, anxiety, and depression. Meth Find Exper Clin Pharmacol. 2007;29(A):1–91.
   PubMedGoogle Scholar
• Cacabelos R. Pharmacogenomics in Alzheimer’s disease. Meth Mol Biol. 2008;448:213–357.
   PubMedGoogle Scholar
• Cacabelos R, Torrellas C, Carrera I. Opportunities in pharmacogenomics for the treatment of Alzheimer’s disease. Future Neurol. 2015;10(3):229–252.
   Web of Science ®Google Scholar
• Davies EA, O’Mahony MS. Adverse drug reactions in special populations - the elderly. Br J Clin Pharmacol. 2015;80(4):796–807.
   PubMed Web of Science ®Google Scholar
• Cacabelos R., editor. World guide for drug use and pharmacogenomics. Corunna (ES): EuroEspes Publishing; 2012.
   Google Scholar
• Just KS, Schneider KL, Schurig M, et al. Falls: the adverse drug reaction of the elderly and the impact of pharmacogenetics. Pharmacogenomics. 2017;18(13):1281–1297.
   PubMed Web of Science ®Google Scholar
• Marcath LA, Coe TD, Hoylman EK, et al. Prevalence of drug-drug interactions in oncology patients enrolled on national clinical trials network oncology clinical trials. BMC Cancer. 2018;18(1):1155.
   PubMedGoogle Scholar
• Zheng WY, Richardson LC, Li L, et al. Drug-drug interactions and their harmful effects in hospitalised patients: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2018;74(1):15–27.
   PubMed Web of Science ®Google Scholar
• Patel RI, Beckett RD. Evaluation of resources for analyzing drug interactions. J Med Libr Assoc. 2016;104(4):290–295.
   PubMed Web of Science ®Google Scholar
• Shoshi A, Müller U, Shoshi A, et al. KALIS - an ehealth system for biomedical risk analysis of drugs. Stud Health Technol Inform. 2017;236:128–135.
   PubMedGoogle Scholar
• Duke JD, Li X, Grannis SJ. Data visualization speeds review of potential adverse drug events in patients on multiple medications. J Biomed Inform. 2010;43(2):326–331.
   PubMed Web of Science ®Google Scholar
• Europharmagenics Database [Internet]. Corunna (ES): EuroEspes Publishing; 2015. Available from: www.europharmagenics.com
   Google Scholar
• Wolters Kluwer clinical drug information [Internet]. USA; 2018. Available from: https://www.wolterskluwercdi.com/lexicomp-online/
   Google Scholar
• PharmGKB. Stanford (US); 2018. Available from: https://www.pharmgkb.org/
   Google Scholar
• Hwang Y, Oh M, Jang G, et al. Identifying the common genetic networks of ADR (adverse drug reaction) clusters and developing an ADR classification model. Mol Biosyst. 2017;13(9):1788–1796.
   PubMedGoogle Scholar
• Samwald M, Miñarro Giménez JA, Boyce RD, et al. Pharmacogenomic knowledge representation, reasoning and genome-based clinical decision support based on OWL 2 DL ontologies. BMC Med Inform Decis Mak. 2015;15:12.
   PubMed Web of Science ®Google Scholar
• Zhang G, Zhang Y, Ling Y, et al. Web resources for pharmacogenomics. Genomics Proteomics Bioinf. 2015;13(1):51–54.
   PubMed Web of Science ®Google Scholar
• Collins SL, Carr DF, Pirmohamed M. Advances in the pharmacogenomics of adverse drug reactions. Drug Saf. 2016;39(1):15–27.
   PubMed Web of Science ®Google Scholar
• Weinshilboum RM, Wang L. Pharmacogenomics: precision medicine and drug response. Mayo Clin Proc. 2017;92(11):1711–1722.
   PubMed Web of Science ®Google Scholar
• Kozyra M, Ingelman-Sundberg M, Lauschke VM. Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response. Genet Med. 2017;19(1):20–29.
   PubMed Web of Science ®Google Scholar
• Zhou ZW, Chen XW, Sneed KB, et al. Clinical association between pharmacogenomics and adverse drug reactions. Drugs. 2015;75(6):589–631.
   PubMed Web of Science ®Google Scholar
• Cacabelos R, Torrellas C. Epigenetics of aging and Alzheimer’s disease: implications for pharmacogenomics and drug response. IJMS. 2015;16:30483–30543.
   Google Scholar
• Cacabelos R, Teijido O, Carril JC, et al. Pharmacoepigenetic processors: epigenetic drugs, drug resistance, toxicoepigenetics and nutriepigenenetics. In: Cacabelos R., editor. Pharmacoepigenetics. London: Academic Press/Elsevier. Forthcoming 2019. DOI:10.1016/13978-0-12-813939-4.00006-1.
   Google Scholar
• Cacabelos R, Tellado I, Cacabelos P. The epigenetic machinery in the life cycle and pharmacoepigenetics. In: Cacabelos R., editor. Pharmacoepigenetics. London: Academic Press/Elsevier. Forthcoming 2019. DOI:10.1016/B978-0-12-813939-4.00001-2.
   Google Scholar
• Cacabelos R. Pleiotropy and promiscuity in pharmacogenomics for the treatment of Alzheimer’s disease and related risk factors. Future Neurol. 2018. DOI:10.2217/fnl–2017
   Web of Science ®Google Scholar
• Cacabelos R, Carril JC, Cacabelos P, et al. Pharmacogenomics of Alzheimer’s disease: genetic determinants of phenotypic variation and therapeutic outcome. J Genomic Med Pharmacogenomics. 2016;1(2):151–209.
   Google Scholar
• Torrellas C, Carril JC, Cacabelos R. Benefits of pharmacogenetics in the management of hypertension. J Pharmacogenomics Pharmacoproteomics. 2014;5:126.
   Google Scholar
• Torrellas C, Carril JC, Cacabelos R. Optimization of antidepressant use with pharmacogenetic strategies. Cur Genomics. 2017;18:442–449.
   PubMed Web of Science ®Google Scholar
• Cacabelos R, Cacabelos P, Torrellas C, et al. Pharmacogenomics of Alzheimer’s disease: novel therapeutic strategies for drug development. Methods Mol Biol. 2014;1175:323–556.
   PubMedGoogle Scholar
• Weeke PE. Pharmacogenetics in cardiovascular medicine. Adv Pharmacol. 2018;83:333–360.
   PubMedGoogle Scholar
• Osanlou O, Pirmohamed M, Daly AK. Pharmacogenetics of adverse drug reactions. Adv Pharmacol. 2018;83:155–190.
   PubMedGoogle Scholar
• Reynolds KK, Pierce DL, Weitendorf F, et al. Avoidable drug-gene conflicts and polypharmacy interactions in patients participating in a personalized medicine program. Per Med. 2017;14(3):221–233.
   PubMed Web of Science ®Google Scholar
• Moyer AM, Caraballo PJ. The challenges of implementing pharmacogenomic testing in the clinic. Expert Rev Pharmacoecon Outcomes Res. 2017;17(6):567–577.
   PubMed Web of Science ®Google Scholar
• Cacabelos R, Torrellas C. Pharmacoepigenomics. In: Tollefsbol T., editor. Medical epigenetics. London: Elsevier; 2016. p. 586-617. DOI:10.1016/B978-0-12-803239-8.00032-6
   Google Scholar
• Cacabelos R, Torrellas C, Teijido O, et al. Pharmacogenetic considerations in the treatment of Alzheimer’s disease. Pharmacogenomics. 2016;17(9):1041–1074.
   PubMed Web of Science ®Google Scholar
• Tang X, Chen S. Epigenetic regulation of cytochrome P450 enzymes and clinical implication. Curr Drug Metab. 2015;16:86–96.
   PubMed Web of Science ®Google Scholar
• Chu SK, Yang HC. Interethnic DNA methylation difference and its implications in pharmacoepigenetics. Epigenomics. 2017;9(11):1437–1454.
   PubMed Web of Science ®Google Scholar
• Lee IS, Kim D. Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes. Arch Pharm Res. 2011;34:1799–1816.
   PubMed Web of Science ®Google Scholar
• Cacabelos R, Fernández-Novoa L, Martínez-Bouza R, et al. Future trends in the pharmacogenomics of brain disorders and dementia: influence of APOE and CYP2D6 variants. Pharmaceuticals. 2010;3:3040–3100.
   Google Scholar
• Xie HG, Kim RB, Wood AJ, et al. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharm Toxicol. 2001;41:815–850.
   PubMed Web of Science ®Google Scholar
• Isaza C, Henao J, Ramírez E, et al. Polymorphic variants of the beta-2-adrenergic receptor (ADRB2) gene and ADRB2-related propanolol-induced dyslipidemia in the Colombian population. Meth Find Exp Clin Pharmacol. 2005;27:237–244.
   PubMedGoogle Scholar
• Apellániz-Ruiz M, Inglada-Pérez L, Naranjo ME, et al. High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme. Pharmacogenomics J. 2015;15(3):288–292.
   PubMed Web of Science ®Google Scholar
• Backman JT, Filppula AM, Niemi M, et al. Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016;68(1):168–241.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Lauschke VM. Comprehensive overview of the pharmacogenetic diversity in Ashkenazi Jews. J Med Genet. 2018;55(9):617–627.
   PubMed Web of Science ®Google Scholar
• Tucci JD, Pumuye PP, Helsby NA, et al. Pharmacogenomics in Papua New Guineans: unique profiles and implications for enhancing drug efficacy while improving drug safety. Pharmacogenet Genomics. 2018;28(6):153–164.
   PubMed Web of Science ®Google Scholar
• Rajman I, Knapp L, Morgan T, et al. African genetic diversity: implications for cytochrome P450-mediated drug metabolism and drug development. EBioMedicine. 2017;17:67–74.
   PubMed Web of Science ®Google Scholar
• Gaio V, Picanço I, Nunes B, et al. Pharmacogenetic profile of a South Portuguese population: results from the pilot study of the European Health Examination Survey in Portugal. Public Health Genomics. 2015;18(3):139–150.
   PubMed Web of Science ®Google Scholar
• Xu C, Li CY, Kong AN. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res. 2005;28:249–268.
   PubMed Web of Science ®Google Scholar
• Haenisch S, Werk AN, Cascorbi I. MicroRNAs and their relevance to ABC transporters. Br J Clin Pharmacol. 2014;77:587–596.
   PubMed Web of Science ®Google Scholar
• Zhou SF, Wang LL, Di YM, et al. Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr Med Chem. 2008;15:1981–2039.
   PubMed Web of Science ®Google Scholar
• Favela-Mendoza AF, Rangel-Villalobos H, Fricke-Galindo I, et al. Genetic variability among Mexican Mestizo and Amerindian populations based on three ABCB1 polymorphisms. Mol Biol Rep. 2018. DOI:10.1007/s11033-018-4419–x.
   PubMed Web of Science ®Google Scholar
• Morgado L, Preite V, Oplaat C, et al. Small RNAs reflect grandparental environments in apomictic dandelion. Mol Biol Evol. 2017;34(8):2035–2040.
   PubMed Web of Science ®Google Scholar
• Vick AD, Burris HH. Epigenetics and health disparities. Curr Epidemiol Rep. 2017;4(1):31–37.
   PubMedGoogle Scholar
• Huang B, Jiang C, Zhang R. Epigenetics: the language of the cell? Epigenomics. 2014;6(1):73–88.
   PubMed Web of Science ®Google Scholar
• Cacabelos R, Torrellas C. Epigenetic drug discovery for Alzheimer’s disease. Expert Opin Drug Discov. 2014;9(9):1059–1086.
   PubMed Web of Science ®Google Scholar
• Cacabelos R. Epigenomic networking in drug development: from pathogenic mechanisms to pharmacogenomics. Drug Dev Res. 2014;75(6):348–365.
   PubMed Web of Science ®Google Scholar
• Tajima S, Suetake I, Takeshita K, et al. Domain structure of the Dnmt1, Dnmt3a, and Dnmt3b DNA methyltransferases. Adv Exp Med Biol. 2016;945:63–86.
   PubMed Web of Science ®Google Scholar
• Guo M, Li X, Zhang L, et al. Accurate quantification of 5-Methylcytosine, 5-Hydroxymethylcytosine, 5-Formylcytosine, and 5-Carboxylcytosine in genomic DNA from breast cancer by chemical derivatization coupled with ultra performance liquid chromatography- electrospray quadrupole time of flight mass spectrometry analysis. Oncotarget. 2017;8(53):91248–91257.
   PubMedGoogle Scholar
• Klungland A, Robertson AB. Oxidized C5-methyl cytosine bases in DNA: 5-Hydroxymethylcytosine; 5-formylcytosine; and 5-carboxycytosine. Free Radic Biol Med. 2017;107:62–68.
   PubMed Web of Science ®Google Scholar
• Koyama M, Kurumizaka H. Structural diversity of the nucleosome. J Biochem. 2018;163(2):85–95.
   PubMed Web of Science ®Google Scholar
• Nizovtseva EV, Clauvelin N, Todolli S, et al. Nucleosome-free DNA regions differentially affect distant communication in chromatin. Nucleic Acids Res. 2017;45(6):3059–3067.
   PubMed Web of Science ®Google Scholar
• Simithy J, Sidoli S, Garcia BA. Integrating proteomics and targeted metabolomics to understand global changes in histone modifications. Proteomics. 2018. DOI:10.1002/pmic.201700309
   PubMed Web of Science ®Google Scholar
• Ru B, Sun J, Tong Y, et al. CR2Cancer: a database for chromatin regulators in human cancer. Nucleic Acids Res. 2018;46(D1):D918–D924.
   PubMed Web of Science ®Google Scholar
• He M, Han Z, Liu L, et al. Chemical biology approaches for investigating the functions of lysine acetyltransferases. Angew Chem Int Ed Engl. 2018;57(5):1162–1184.
   PubMed Web of Science ®Google Scholar
• Sabari BR, Zhang D, Allis CD, et al. Metabolic regulation of gene expression through histone acylations. Nat Rev Mol Cell Biol. 2017;18(2):90–101.
   PubMed Web of Science ®Google Scholar
• Ernst C, Morton CC. Identification and function of long non-coding RNA. Front Cell Neurosci. 2013;7:168.
   PubMed Web of Science ®Google Scholar
• Li LC. Chromatin remodeling by the small RNA machinery in mammalian cells. Epigenetics. 2014;9:45–52.
   PubMed Web of Science ®Google Scholar
• Rosenblat JD, Lee Y, McIntyre RS. The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: a meta-analysis. J Affect Disord. 2018;241:484–491.
   PubMed Web of Science ®Google Scholar
• Cacabelos R, Martínez-Bouza R. Genomics and pharmacogenomics of schizophrenia. CNS Neurosci Ther. 2010. DOI:10.1111/j.1755-5949.2010.00187.x
   Web of Science ®Google Scholar
• Cacabelos R, Martínez-Bouza R, Carril JC, et al. Genomics and pharmacogenomics of brain disorders. Curr Pharm Biotech. 2012;13:674–725.
   PubMed Web of Science ®Google Scholar
• Cacabelos R, Torrellas C. Pharmacogenomics of antidepressants. HSOA J Psychiatry Depress Anxiety. 2015;1:001.
   Google Scholar
• Cacabelos R, Cacabelos P, Aliev G. Genomics and pharmacogenomics of antipsychotic drugs. Open J Psychiatry. 2013;3(46–139).
   Google Scholar
• Spina E, de Leon J. Clinical applications of CYP genotyping in psychiatry. J Neural Transm. 2015;122(1):5–28.
   PubMed Web of Science ®Google Scholar
• Seripa D, Lozupone M, Miscio G, et al. CYP2D6 genotypes in revolving door patients with bipolar disorders: a case series. Medicine (Baltimore). 2018;97(37):e11998.
   PubMed Web of Science ®Google Scholar
• Pisanu C, Heilbronner U, Squassina A. The role of pharmacogenomics in bipolar disorder: moving towards precision medicine. Mol Diagn Ther. 2018;22(4):409–420.
   PubMed Web of Science ®Google Scholar
• Seripa D, Lozupone M, Stella E, et al. Psychotropic drugs and CYP2D6 in late-life psychiatric and neurological disorders what do we know? Expert Opin Drug Saf. 2017;16(12):1373–1385.
   PubMed Web of Science ®Google Scholar
• Chavan BS, Kaur G, Gupta D, et al. A prospective study to evaluate the effect of CYP2D6 polymorphism on plasma level of risperidone and its metabolite in North Indian patients with schizophrenia. Indian J Psychol Med. 2018;40(4):335–342.
   PubMedGoogle Scholar
• de Leon J, Susce MT, Pan RM, et al. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry. 2005;66(1):15–27.
   PubMed Web of Science ®Google Scholar
• Cartwright AL, Wilby KJ, Corrigan S, et al. Pharmacogenetics of risperidone: a systematic review of the clinical effects of CYP2D6 polymorphisms. Ann Pharmacother. 2013;47(3):350–360.
   PubMed Web of Science ®Google Scholar
• Gunes A, Spina E, Dahl ML, et al. ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety. Ther Drug Monit. 2008;30(5):628–633.
   PubMed Web of Science ®Google Scholar
• Correia CT, Almeida JP, Santos PE, et al. Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions. Pharmacogenomics J. 2010;10(5):418–430.
   PubMed Web of Science ®Google Scholar
• Brennan MD. Pharmacogenetics of second-generation antipsychotics. Pharmacogenomics. 2014;15(6):869–884.
   PubMed Web of Science ®Google Scholar
• Cabaleiro T, López-Rodríguez R, Román M, et al. Pharmacogenetics of quetiapine in healthy volunteers: association with pharmacokinetics, pharmacodynamics, and adverse effects. Int Clin Psychopharmacol. 2015;30(2):82–88.
   PubMed Web of Science ®Google Scholar
• Numata S, Umehara H, Ohmori T, et al. Clozapine pharmacogenetic studies in schizophrenia: efficacy and agranulocytosis. Front Pharmacol. 2018;9:1049.
   PubMed Web of Science ®Google Scholar
• Vasudev K, Choi YH, Norman R, et al. Genetic determinants of clozapine-induced metabolic side effects. Can J Psychiatry. 2017;62(2):138–149.
   PubMed Web of Science ®Google Scholar
• Girardin FR, Poncet A, Perrier A, et al. Cost-effectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine. Pharmacogenomics J. 2018. DOI:10.1038/s41397-017-0004-2.
   PubMed Web of Science ®Google Scholar
• Zastrozhin MS, Brodyansky VM, Skryabin VY, et al. Pharmacodynamic genetic polymorphisms affect adverse drug reactions of haloperidol in patients with alcohol-use disorder. Pharmgenomics Pers Med. 2017;10:209–215.
   PubMed Web of Science ®Google Scholar
• Šimić I, Potočnjak I, Kraljičković I, et al. CYP2D6 *6/*6 genotype and drug interactions as cause of haloperidol-induced extrapyramidal symptoms. Pharmacogenomics. 2016;17(13):1385–1389.
   PubMed Web of Science ®Google Scholar
• Al Hadithy AF, Ivanova SA, Pechlivanoglou P, et al. Missense polymorphisms in three oxidative-stress enzymes (GSTP1, SOD2, and GPX1) and dyskinesias in Russian psychiatric inpatients from Siberia. Hum Psychopharmacol. 2010;25(1):84–91.
   PubMed Web of Science ®Google Scholar
• Fischer S, Gardini E, Haas F, et al. Polymorphisms in genes related to the hypothalamic-pituitary-adrenal axis and antidepressant response – systematic review. Neurosci Biobehav Rev. 2018;S0149-7634(18)30431–7.
   Google Scholar
• Clark SL, Adkins DE, Aberg K, et al. Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D. Psychol Med. 2012;42(6):1151–1162.
   PubMed Web of Science ®Google Scholar
• Zhu J, Klein-Fedyshin M, Stevenson JM. Serotonin transporter gene polymorphisms and selective serotonin reuptake inhibitor tolerability: review of pharmacogenetic evidence. Pharmacotherapy. 2017;37(9):1089–1104.
   PubMed Web of Science ®Google Scholar
• Stevenson JM, Bishop JR. Genetic determinants of selective serotonin reuptake inhibitor related sexual dysfunction. Pharmacogenomics. 2014;15(14):1791–1806.
   PubMed Web of Science ®Google Scholar
• Rahikainen AL, Palo JU, Haukka J, et al. Post-mortem analysis of suicide victims shows ABCB1 haplotype 1236T-2677T-3435T as a candidate predisposing factor behind adverse drug reactions in females. Pharmacogenet Genomics. 2018;28(4):99–106.
   PubMed Web of Science ®Google Scholar
• Saiz-Rodríguez M, Belmonte C, Román M, et al. Effect of polymorphisms on the pharmacokinetics, pharmacodynamics and safety of sertraline in healthy volunteers. Basic Clin Pharmacol Toxicol. 2018;122(5):501–511.
   PubMed Web of Science ®Google Scholar
• Tóth K, Csukly G, Sirok D, et al. Optimization of clonazepam therapy adjusted to patient’s CYP3A status and NAT2 genotype. Int J Neuropsychopharmacol. 2016. DOI:10.1093/ijnp/pyw083.
   Web of Science ®Google Scholar
• Zastrozhin MS, Antonenko AP, Nesterenko EV, et al. Effects of CYP2C19*17 polymorphisms on the efficacy and safety of bromodigyrochlorophenylbenzodiazepine in patients with anxiety disorder and comorbid alcohol use disorder. Drug Metab Pers Ther. 2018. DOI:10.1515/dmpt-2018-001.
   PubMedGoogle Scholar
• Fricke-Galindo I, LLerena A, Jung-Cook H, et al. Carbamazepine adverse drug reactions. Expert Rev Clin Pharmacol. 2018;11(7):705–718.
   PubMed Web of Science ®Google Scholar
• Yip VL, Pirmohamed M. The HLA-A*31:01 allele: influence on carbamazepine treatment. Pharmgenomics Pers Med. 2017;10:29–38.
   PubMed Web of Science ®Google Scholar
• Chung WH, Hung S, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004;428(6982):486.
   PubMed Web of Science ®Google Scholar
• Chen P, Lin JJ, Lu CS, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med. 2011;364(12):1126–1133.
   PubMed Web of Science ®Google Scholar
• Djordjevic N, Jankovic SM, Milovanovic JR. Pharmacokinetics and pharmacogenetics of carbamazepine in children. Eur J Drug Metab Pharmacokinet. 2017;42(5):729–744.
   PubMed Web of Science ®Google Scholar
• Kim WJ, Lee JH, Yi J, et al. A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy. Pharmacogenet Genomics. 2010;20(4):249–256.
   PubMed Web of Science ®Google Scholar
• Chung WH, Chang WC, Lee YS, et al. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. JAMA. 2014;312(5):525–534.
   PubMed Web of Science ®Google Scholar
• Yampayon K, Sukasem C, Limwongse C, et al. Influence of genetic and non-genetic factors on phenytoin-induced severe cutaneous adverse drug reactions. Eur J Clin Pharmacol. 2017;73(7):855–865.
   PubMed Web of Science ®Google Scholar
• Chang CC, Ng CC, Too CL, et al. Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population. Pharmacogenomics J. 2017;17(2):170–173.
   PubMed Web of Science ®Google Scholar
• Su SC, Chen CB, Chang WC, et al. HLA alleles and CYP2C9*3 as predictors of phenytoin hypersensitivity in East Asians. Clin Pharmacol Ther. 2018. DOI:10.1002/cpt.1190.
   Web of Science ®Google Scholar
• Fricke-Galindo I, Martínez-Juárez IE, Monroy-Jaramillo N, et al. HLA-A*02:01:01/-B*35:01:01/-C*04:01:01 haplotype associated with lamotrigine-induced maculopapular exanthema in Mexican Mestizo patients. Pharmacogenomics. 2014;15(15):1881–1891.
   PubMed Web of Science ®Google Scholar
• Nelson EM, Philbrick AM. Avoiding serotonin syndrome: the nature of the interaction between tramadol and selective serotonin reuptake inhibitors. Ann Pharmacother. 2012;46(12):1712–1716.
   PubMed Web of Science ®Google Scholar
• Cacabelos R. Donepezil in Alzheimer’s disease: from conventional trials to pharmacogenetics. Neuropsychiat Dis Treat. 2007;3:303–333.
   PubMedGoogle Scholar
• Cacabelos R, Llovo R, Fraile C, et al. Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer’s disease pharmacogenetics. Cur Alzheimer Res. 2007;4:479–500.
   PubMed Web of Science ®Google Scholar
• Cacabelos R, Goldgaber D, Vostrov A, et al. APOE-TOMM40 in the pharmacogenomics of demetia. J Pharmacogenomics Pharmacoproteomics. 2014;5:135.
   Google Scholar
• Parkinson’s CR. disease: from pathogenesis to pharmacogenomics. Int J Mol Sci. 2017;2017(18):551.
   Google Scholar
• Cacabelos R. Pharmacogenomics of Alzheimer’s and Parkinson’s diseases. Neurosci Lett. 2018; [cited 2018 Sept 18]. DOI:10.1016/j.neulet.
   PubMedGoogle Scholar
• Cacabelos R, Fernández-Novoa L, Alejo R, et al. E-PodoFavalin-15999 (Atremorine®)-induced dopamine response in Parkinson’s Disease: pharmacogenetics-related effects. J Genomic Med Pharmacogenomics. 2016;1:1–26.
   Google Scholar
• Hajj A, Ghosn M, Mourad D, et al. Lethal hepatotoxicity following 5-fluorouracil/cisplatin chemotherapy: a relevant case report. Per Med. 2017;14(3):197–201.
   PubMed Web of Science ®Google Scholar
• Moradi-Marjaneh R, Khazaei M, Seifi S, et al. Pharmacogenetics of anticancer drug sensitivity and toxicity in colorectal cancer. Curr Pharm Des. 2018;24(23):2710–2718.
   PubMed Web of Science ®Google Scholar
• Abaji R, Ceppi F, Patel S, et al. Genetic risk factors for VIPN in childhood acute lymphoblastic leukemia patients identified using whole-exome sequencing. Pharmacogenomics. 2018;19(15):1181–1193.
   PubMed Web of Science ®Google Scholar
• Bray J, Sludden J, Griffin MJ, et al. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer. 2010;102(6):1003–1009.
   PubMed Web of Science ®Google Scholar
• Inoue K, Sonobe M, Kawamura Y, et al. Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy. Tohoku J Exp Med. 2013;229(2):107–114.
   PubMed Web of Science ®Google Scholar
• Zaïr ZM, Singer DR. Efflux transporter variants as predictors of drug toxicity in lung cancer patients: systematic review and meta-analysis. Pharmacogenomics. 2016;17(9):1089–1112.
   PubMed Web of Science ®Google Scholar
• Zenke Y, Umemura S, Sugiyama E, et al. Successful treatment with afatinib after grade 3 hepatotoxicity induced by both gefitinib and erlotinib in EGFR mutation-positive non-small cell lung cancer. Lung Cancer. 2016;99(1–3):6.
   Google Scholar
• Patel ND, Chakrabory K, Messmer G, et al. Severe sunitinib-induced myelosuppression in a patient with a CYP 3A4 polymorphism. J Oncol Pharm Pract. 2018;24(8):623–626.
   PubMed Web of Science ®Google Scholar
• Maeda A, Ando H, Ura T, et al. Association between ABCG2 and SLCO1B1 polymorphisms and adverse drug reactions to regorafenib: a preliminary study. Int J Clin Pharmacol Ther. 2017;55(5):409–415.
   PubMed Web of Science ®Google Scholar
• Quintanilha JCF, de Sousa VM, Visacri MB, et al. Involvement of cytochrome P450 in cisplatin treatment: implications for toxicity. Cancer Chemother Pharmacol. 2017;80(2):223–233.
   PubMed Web of Science ®Google Scholar
• Sini V, Botticelli A, Lunardi G, et al. Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients. Pharmacogenomics. 2017;18(8):821–830.
   PubMed Web of Science ®Google Scholar
• Ross CJ, Katzov-Eckert H, Dubé MP, et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet. 2009;41(12):1345–1349.
   PubMed Web of Science ®Google Scholar
• Drögemöller BI, Monzon JG, Bhavsar AP, et al. Association between SLC16A5 genetic variation and cisplatin-induced ototoxic effects in adult patients with testicular cancer. JAMA Oncol. 2017;3(11):1558–1562.
   PubMed Web of Science ®Google Scholar
• Del Re M, Latiano T, Fidilio L, et al. Unusual gastrointestinal and cutaneous toxicities by bleomycin, etoposide, and cisplatin: a case report with pharmacogenetic analysis to personalize treatment. Epma J. 2017;8(1):69–73.
   PubMed Web of Science ®Google Scholar
• Lambrecht L, Sleurs C, Labarque V, et al. The role of the MTHFR C677T polymorphism in methotrexate-induced toxicity in pediatric osteosarcoma patients. Pharmacogenomics. 2017;18(8):787–795.
   PubMed Web of Science ®Google Scholar
• Meulendijks D, Cats A, Beijnen JH, et al. Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - ready for clinical practice? Cancer Treat Rev. 2016;50:23–34.
   PubMed Web of Science ®Google Scholar
• Loganayagam A, Arenas Hernandez M, Corrigan A, et al. Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity. Br J Cancer. 2013;108(12):2505–2515.
   PubMed Web of Science ®Google Scholar
• Pellicer M, García-González X, García MI, et al. Identification of new SNPs associated with severe toxicity to capecitabine. Pharmacol Res. 2017;120:133–137.
   PubMed Web of Science ®Google Scholar
• Lam SW, Guchelaar HJ, Boven E. The role of pharmacogenetics in capecitabine efficacy and toxicity. Cancer Treat Rev. 2016;50:9–22.
   PubMed Web of Science ®Google Scholar
• Fernandez-Rozadilla C, Cazier JB, Moreno V, et al. Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration. Pharmacogenomics J. 2013;13(3):209–217.
   PubMed Web of Science ®Google Scholar
• Yin JY, Meng XG, Qian CY, et al. Association of positively selected eIF3a polymorphisms with toxicity of platinum-based chemotherapy in NSCLC patients. Acta Pharmacol Sin. 2015;36(3):375–384.
   PubMed Web of Science ®Google Scholar
• Zheng D, Chen Y, Gao C, et al. Polymorphisms of p53 and MDM2 genes are associated with severe toxicities in patients with non-small cell lung cancer. Cancer Biol Ther. 2014;15(11):1542–1551.
   PubMed Web of Science ®Google Scholar
• Tulsyan S, Chaturvedi P, Agarwal G, et al. Pharmacogenetic influence of GST polymorphisms on anthracycline-based chemotherapy responses and toxicity in breast cancer patients: a multi-analytical approach. Mol Diagn Ther. 2013;17(6):371–379.
   PubMed Web of Science ®Google Scholar
• Magdy T, Burmeister BT, Burridge PW. Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: what is missing? Pharmacol Ther. 2016;168:113–125.
   PubMed Web of Science ®Google Scholar
• Aminkeng F, Bhavsar AP, Visscher H, et al. A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. Nat Genet. 2015;47(9):1079–1084.
   PubMed Web of Science ®Google Scholar
• Aminkeng F, Ross CJD, Rassekh SR, et al. Pharmacogenomic screening for anthracycline-induced cardiotoxicity in childhood cancer. Br J Clin Pharmacol. 2017;83(5):1143–1145.
   PubMed Web of Science ®Google Scholar
• Beitelshees AL, Voora D, Lewis JP. Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics. Pharmgenomics Pers Med. 2015;8:43–61.
   PubMed Web of Science ®Google Scholar
• Liu J, Jiang HH, Wu DK, et al. Effect of gene polymorphims on the warfarin treatment at initial stage. Pharmacogenomics J. 2017;17(1):47–52.
   PubMed Web of Science ®Google Scholar
• Li J, Wang Y, Wang H. Distribution of CYP2C19 polymorphisms in Mongolian and Han nationals and the choice of specific antiplatelet drugs. Int J Clin Pharm. 2017;39(4):791–797.
   PubMed Web of Science ®Google Scholar
• Vazquez SR. Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions. Blood. 2018;132(21):2230–2239.
   PubMed Web of Science ®Google Scholar
• Sennesael AL, Larock AS, Douxfils J, et al. Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study. Thromb J. 2018;16:28.
   PubMed Web of Science ®Google Scholar
• Ma TK, Lam YY, Tan VP, et al. Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions? Br J Clin Pharmacol. 2011;72(4):697–706.
   PubMed Web of Science ®Google Scholar
• Vasudeva K, Chaurasia P, Singh S, et al. Genetic signatures in ischemic stroke: focus on aspirin resistance. CNS Neurol Disord Drug Targets. 2017;16(9):974–982.
   PubMed Web of Science ®Google Scholar
• Yang L, Lu YL, Wang HJ, et al. [Pharmacogenomics study of 620 whole-exome sequencing: focusing on aspirin application]. Zhonghua Er Ke Za Zhi. 2016;54(5):332–336.
   PubMedGoogle Scholar
• Richardson M, Kirkham J, Dwan K, et al. Influence of genetic variants on toxicity to anti-tubercular agents: a systematic review and meta-analysis (protocol). Syst Rev. 2017;6(1):142.
   PubMedGoogle Scholar
• Azuma J, Ohno M, Kubota R, et al; Pharmacogenetics-based tuberculosis therapy research group. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. Eur J Clin Pharmacol. 2013;69(5):1091–1101.
   Google Scholar
• Richardson M, Kirkham J, Dwan K, et al. CYP genetic variants and toxicity related to anti-tubercular agents: a systematic review and meta-analysis. Syst Rev. 2018;7(1):204.
   PubMedGoogle Scholar
• Kim SH, Kim SH, Yoon HJ, et al. TNF-α genetic polymorphism −308G/A and antituberculosis drug-induced hepatitis. Liver Int. 2012;32(5):809–814.
   PubMed Web of Science ®Google Scholar
• Agarwal D, Udoji MA, Trescot A. Genetic testing for opioid pain management: a primer. Pain Ther. 2017;6(1):93–105.
   PubMed Web of Science ®Google Scholar
• Ahmad T, Valentovic MA, Rankin GO. Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics. Biochem Pharmacol. 2018;153:196–204.
   PubMed Web of Science ®Google Scholar
• Volpe DA, Xu Y, Sahajwalla CG, et al. Methadone metabolism and drug-drug interactions: in Vitro and In Vivo literature review. J Pharm Sci. 2018;107(12):2983–2991.
   PubMed Web of Science ®Google Scholar
• Squillace N, Bozzi G, Colella E, et al. Darunavir-cobicistat-emtricitabine-tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era. Drug Des Devel Ther. 2018;12:3635–3643.
   PubMed Web of Science ®Google Scholar
• Arruda MB, Campagnari F, de Almeida TB, et al. Single nucleotide polymorphisms in cellular drug transporters are associated with intolerance to antiretroviral therapy in Brazilian HIV-1 positive individuals. PLoS One. 2016 Sep;11(9):e0163170.
   PubMed Web of Science ®Google Scholar
• Ciccacci C, Latini A, Politi C, et al. Impact of glutathione transferases genes polymorphisms in nevirapine adverse reactions: a possible role for GSTM1 in SJS/TEN susceptibility. Eur J Clin Pharmacol. 2017;73(10):1253–1259.
   PubMed Web of Science ®Google Scholar
• Swart M, Evans J, Skelton M, et al. An expanded analysis of pharmacogenetics determinants of efavirenz response that includes 3ʹ-UTR single nucleotide polymorphisms among Black South African HIV/AIDS patients. Front Genet. 2016;6:356.
   PubMed Web of Science ®Google Scholar
• Gallien S, Journot V, Loriot M, et al. Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms: a substudy of the ANRS ALIZE trial. HIV Med. 2017;18(8):537–545.
   PubMed Web of Science ®Google Scholar
• de Oliveira Rodrigues R, Helena Barem Rabenhorst S, Germano de Carvalho P, et al. Association of IL10, IL4, IFNG, and CTLA4 gene polymorphisms with efavirenz hypersensitivity reaction in patients infected with human immunodeficiency virus. Jpn J Infect Dis. 2017;70(4):430–436.
   PubMed Web of Science ®Google Scholar
• Kellick K. Organic ion transporters and statin drug interactions. Curr Atheroscler Rep. 2017;19(12):65.
   PubMed Web of Science ®Google Scholar
• Alam K, Crowe A, Wang X, et al. Regulation of Organic Anion Transporting Polypeptides (OATP) 1B1- and OATP1B3-mediated transport: an updated review in the context of OATP-mediated drug-drug interactions. Int J Mol Sci. 2018;19(3):E855.
   PubMed Web of Science ®Google Scholar
• Danielak D, Karaźniewicz-Łada M, Główka F. Assessment of the risk of rhabdomyolysis and myopathy during concomitant treatment with ticagrelor and statins. Drugs. 2018. DOI:10.1007/s40265-018-0947-x
   PubMed Web of Science ®Google Scholar
• Maeda K. Organic anion transporting polypeptide (OATP)1B1 and OATP1B3 as important regulators of the pharmacokinetics of substrate drugs. Biol Pharm Bull. 2015;38(2):155–168.
   PubMed Web of Science ®Google Scholar
• Siddiqui M, Maroteau C, Veluchamy A, et al. A common missense variant of LILRB5 is associated with statin intolerance and myalgia. Eur Heart J. 2017 Dec;38(48):3569–3575.
   PubMed Web of Science ®Google Scholar
• Bellosta S, Corsini A. Statin drug interactions and related adverse reactions: an update. Expert Opin Drug Saf. 2018 Jan;17(1):25–37.
   PubMed Web of Science ®Google Scholar
• Marchesi F, Girmenia C, Goffredo BM, et al. Isavuconazole: case report and pharmacokinetic considerations. Chemotherapy. 2018 Nov;63(5):253–256.
   PubMed Web of Science ®Google Scholar
• Urban TJ, Nicoletti P, Chalasani N, et al. Minocycline hepatotoxicity: clinical characterization and identification of HLA-B∗35:02 as a risk factor. J Hepatol. 2017 Jul;67(1):137–144.
   PubMed Web of Science ®Google Scholar
• Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005;102(11):4134–4139.
   PubMed Web of Science ®Google Scholar
• Chung WH, Chang WC, Stocker SL, et al. Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin. Ann Rheum Dis. 2015;74(12):2157–2164.
   PubMed Web of Science ®Google Scholar
• Wu R, Cheng YJ, Zhu LL, et al. Impact of HLA-B*58:01 allele and allopurinol-induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies. Oncotarget. 2016 Dec;7(49):81870–81879.
   PubMedGoogle Scholar
• Ke CH, Chung WH, Wen YH, et al. Cost-effectiveness analysis for genotyping before allopurinol treatment to prevent severe cutaneous adverse drug reactions. J Rheumatol. 2017 Jun;44(6):835–843.
   PubMed Web of Science ®Google Scholar
• Plumpton CO, Alfirevic A, Pirmohamed M, et al. Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout. Rheumatology (Oxford). 2017 Oct;56(10):1729–1739.
   PubMed Web of Science ®Google Scholar
• Rollason V, Samer CF, Daali Y, et al. Prediction by pharmacogenetics of safety and efficacy of non-steroidal anti- inflammatory drugs: a review. Curr Drug Metab. 2014 Mar;15(3):326–343.
   PubMed Web of Science ®Google Scholar
• Kakuta Y, Kinouchi Y, Shimosegawa T. Pharmacogenetics of thiopurines for inflammatory bowel disease in East Asia: prospects for clinical application of NUDT15 genotyping. J Gastroenterol. 2018;53(2):172–180.
   PubMed Web of Science ®Google Scholar
• Yin D, Xia X, Zhang J, et al. Impact of NUDT15 polymorphisms on thiopurines-induced myelotoxicity and thiopurines tolerance dose. Oncotarget. 2017;8(8):13575–13585.
   PubMedGoogle Scholar
• Asadov C, Aliyeva G, Mustafayeva K. Thiopurine S-methyltransferase as a pharmacogenetic biomarker: significance of testing and review of major methods. Cardiovasc Hematol Agents Med Chem. 2017;15(1):23–30.
   PubMedGoogle Scholar
• Hu M, Piller NB. Strategies for avoiding benzopyrone hepatotoxicity in lymphedema management-the role of pharmacogenetics, metabolic enzyme gene identification, and patient selection. Lymphat Res Biol. 2017;15(4):317–323.
   PubMed Web of Science ®Google Scholar
• Sychev DA, Shih NV, Kalle EG, et al. [Pharmacogenetic approaches to predicting the efficiency and safety of amlodipine in patients with arterial hypertension]. Biomed Khim. 2017;63(5):432–439.
   PubMedGoogle Scholar
• Hallberg P, Persson M, Axelsson T, et al. Genetic variants associated with angiotensin-converting enzyme inhibitor-induced cough: a genome-wide association study in a swedish population. Pharmacogenomics. 2017;18(3):201–213.
   PubMed Web of Science ®Google Scholar
• Mahmoudpour SH, Veluchamy A, Siddiqui MK, et al. Meta-analysis of genome-wide association studies on the intolerance of angiotensin-converting enzyme inhibitors. Pharmacogenet Genomics. 2017;27(3):112–119.
   PubMed Web of Science ®Google Scholar
• Mugoša S, Djordjević N, Djukanović N, et al. Factors affecting the development of adverse drug reactions to β-blockers in hospitalized cardiac patient population. Patient Prefer Adherence. 2016;10:1461–1469.
   PubMed Web of Science ®Google Scholar
• Wojtczak A, Wojtczak M, Skrętkowicz J. The relationship between plasma concentration of metoprolol and CYP2D6 genotype in patients with ischemic heart disease. Pharmacol Rep. 2014;66(3):511–514.
   PubMed Web of Science ®Google Scholar
• Chatzopoulos GS, Koidou VP, Wolff LF. Systematic review of cyclosporin A-induced gingival overgrowth and genetic predisposition. Quintessence Int. 2017;48(9):711–724.
   PubMed Web of Science ®Google Scholar
• Potočnjak I, Likić R, Šimić I, et al. Dapsone-induced agranulocytosis-possible involvement of low-activity N-acetyltransferase 2. Fundam Clin Pharmacol. 2017;31(5):580–586.
   PubMedGoogle Scholar
• Yusof W, Hua GS. Gene, ethnic and gender influences predisposition of adverse drug reactions to artesunate among Malaysians. Toxicol Mech Methods. 2012;22(3):184–192.
   PubMed Web of Science ®Google Scholar
• Dadheech S, Rao AV, Shaheen U, et al. Three most common nonsynonymous UGT1A6*2 polymorphisms (Thr181Ala, Arg184Ser and Ser7Ala) and therapeutic response to deferiprone in β-thalassemia major patients. Gene. 2013;531(2):301–305.
   PubMed Web of Science ®Google Scholar
• Staiger H, Schaeffeler E, Schwab M, et al. Pharmacogenetics: implications for modern type 2 diabetes therapy. Rev Diabet Stud. 2015;12(3–4):363–376. Fall-Winter.
   PubMedGoogle Scholar
• Alachkar H, Fulton N, Sanford B, et al. Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia. Pharmacogenomics J. 2017;17(3):274–279.
   PubMed Web of Science ®Google Scholar
• Cecchin E, De Mattia E, Mazzon G, et al. A pharmacogenetic survey of androgen receptor (CAG)n and (GGN)n polymorphisms in patients experiencing long term side effects after finasteride discontinuation. Int J Biol Markers. 2014;29(4):e310–6.
   PubMed Web of Science ®Google Scholar
• Aziz RK, Hegazy SM, Yasser R, et al. Drug pharmacomicrobiomics and toxicomicrobiomics: from scattered reports to systematic studies of drug-microbiome interactions. Expert Opin Drug Metab Toxicol. 2018;14(10):1043–1055.
   PubMed Web of Science ®Google Scholar
• Zaza G, Granata S, Tomei P, et al. Personalization of the immunosuppressive treatment in renal transplant recipients: the great challenge in “omics” medicine. Int J Mol Sci. 2015;16(2):4281–4305.
   PubMed Web of Science ®Google Scholar
• Gore R, Chugh PK, Tripathi CD, et al. Pediatric off-label and unlicensed drug use and its implications. Curr Clin Pharmacol. 2017;12(1):18–25.
   PubMed Web of Science ®Google Scholar
• Sbaih N, Buss B, Goyal D, et al. Potentially serious drug interactions resulting from the pretravel health encounter. Open Forum Infect Dis. 2018. DOI:10.1093/ofid/ofy266.
   PubMed Web of Science ®Google Scholar
• Jung JW, Kim JY, Park IW, et al. Genetic markers of severe cutaneous adverse reactions. Korean J Intern Med. 2018;33(5):867–875.
   PubMed Web of Science ®Google Scholar
• Gerogianni K, Tsezou A, Dimas DK. Drug-Induced Skin Adverse Reactions: the Role of Pharmacogenomics in Their Prevention. Mol Diagn Ther. 2018;22(3):297–314.
   PubMed Web of Science ®Google Scholar
• Chen CB, Abe R, Pan RY, et al. An Updated Review of the Molecular Mechanisms in Drug Hypersensitivity. J Immunol Res. 2018;2018:6431694.
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M, Mkrtchian S, Zhou Y, et al. Integrating rare genetic variants into pharmacogenetic drug response predictions. Hum Genomics. 2018;12(1):26.
   PubMedGoogle Scholar
• Imatoh T, Sai K, Saito Y. Pharmacogenomic information in the Warning section of drug labels: a comparison between labels in the United States and those in five other countries/regions. J Clin Pharm Ther. 2018;43(4):493–499.
   PubMed Web of Science ®Google Scholar
• Kim GJ, Lee SY, Park JH, et al. Role of preemptive genotyping in preventing serious adverse drug events in South Korean patients. Drug Saf. 2017;40(1):65–80.
   PubMed Web of Science ®Google Scholar
• Franconi F, Campesi I. Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women. Br J Pharmacol. 2014;171(3):580–594.
   PubMed Web of Science ®Google Scholar
• Plumpton CO, Pirmohamed M, Hughes DA. Cost-effectiveness of panel tests for multiple pharmacogenes associated with adverse drug reactions: an evaluation framework. Clin Pharmacol Ther. 2018. DOI:10.1002/cpt.1312
   Google Scholar
• Schuck RN, Grillo JA. Pharmacogenomic biomarkers: an FDA perspective on utilization in biological product labeling. AAPS J. 2016;18(3):573–577.
   PubMed Web of Science ®Google Scholar
• Tan-Koi WC, Lim ES, Teo YY. Health regulatory communications of well-established safety-related pharmacogenomics associations in six developed countries: an evaluation of alignment. Pharmacogenomics J. 2017;17(2):121–127.
   PubMed Web of Science ®Google Scholar
• Shimazawa R, Ikeda M. Differences in pharmacogenomic biomarker information in package inserts from the United States, the United Kingdom and Japan. J Clin Pharm Ther. 2013;38(6):468–475.
   PubMed Web of Science ®Google Scholar
• Ishiguro A, Yagi S, Uyama Y. Characteristics of pharmacogenomics/biomarker-guided clinical trials for regulatory approval of anti-cancer drugs in Japan. J Hum Genet. 2013;58(6):313–316.
   PubMed Web of Science ®Google Scholar
• Bondon-Guitton E, Despas F, Becquemont L. The contribution of pharmacogenetics to pharmacovigilance. Therapie. 2016;71(2):223–228.
   PubMed Web of Science ®Google Scholar
• Awada Z, Zgheib NK. Pharmacogenovigilance: a pharmacogenomics pharmacovigilance program. Pharmacogenomics. 2014;15(6):845–856.
   PubMed Web of Science ®Google Scholar
• Blankstein S. Pharmacogenomics: history, barriers, and regulatory solutions. Food Drug Law J. 2014;69(2):273–314.
   PubMed Web of Science ®Google Scholar
• Maliepaard M, Nofziger C, Papaluca M, et al. Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective. Nat Rev Drug Discov. 2013;12(2):103–115.
   PubMed Web of Science ®Google Scholar
• Liou SY, Stringer F, Hirayama M. The impact of pharmacogenomics research on drug development. Drug Metab Pharmacokinet. 2012;27(1):2–8.
   PubMed Web of Science ®Google Scholar
• Haga SB, O’Daniel JM, Tindall GM, et al. Survey of US public attitudes toward pharmacogenetic testing. Pharmacogenomics J. 2012;12(3):197–204.
   PubMed Web of Science ®Google Scholar
• Nishimura AA, Shirts BH, Salama J, et al. Physician perspectives of CYP2C19 and clopidogrel drug-gene interaction active clinical decision support alerts. Int J Med Inform. 2016;86:117–125.
   PubMed Web of Science ®Google Scholar
• Obara T, Abe S, Satoh M, et al. Awareness regarding clinical application of pharmacogenetics among Japanese pharmacists. Pharmgenomics Pers Med. 2015;8:35–41.
   PubMed Web of Science ®Google Scholar
• Dunnenberger HM, Crews KR, Hoffman JM, et al. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annu Rev Pharmacol Toxicol. 2015;55:89–106.
   PubMed Web of Science ®Google Scholar